Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
Status:
Terminated
Trial end date:
2018-08-20
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy profile of different treatment regimens of Ruxolitinib
(INCB018424) administered to two groups of patients; those with polycythemia vera (PV) and
those with essential thrombocythemia (ET). Patients in each group were refractory to
hydroxyurea or for whom hydroxyurea is contraindicated.